MX2024010938A - Capsides de variantes del virus adeno-asociado con tropismo pulmonar mejorado y usos de las mismas - Google Patents

Capsides de variantes del virus adeno-asociado con tropismo pulmonar mejorado y usos de las mismas

Info

Publication number
MX2024010938A
MX2024010938A MX2024010938A MX2024010938A MX2024010938A MX 2024010938 A MX2024010938 A MX 2024010938A MX 2024010938 A MX2024010938 A MX 2024010938A MX 2024010938 A MX2024010938 A MX 2024010938A MX 2024010938 A MX2024010938 A MX 2024010938A
Authority
MX
Mexico
Prior art keywords
adeno
associated virus
virus variant
improved lung
tropism
Prior art date
Application number
MX2024010938A
Other languages
English (en)
Spanish (es)
Inventor
Peter Francis
Melissa A Kotterman
Julie Nye
Roxanne Croze
Original Assignee
4D Molecular Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4D Molecular Therapeutics Inc filed Critical 4D Molecular Therapeutics Inc
Publication of MX2024010938A publication Critical patent/MX2024010938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024010938A 2022-03-07 2024-09-06 Capsides de variantes del virus adeno-asociado con tropismo pulmonar mejorado y usos de las mismas MX2024010938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317450P 2022-03-07 2022-03-07
PCT/US2023/063789 WO2023172873A2 (en) 2022-03-07 2023-03-06 Adeno-associated virus variant capsids with improved lung tropism and uses thereof

Publications (1)

Publication Number Publication Date
MX2024010938A true MX2024010938A (es) 2025-04-02

Family

ID=87935918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010938A MX2024010938A (es) 2022-03-07 2024-09-06 Capsides de variantes del virus adeno-asociado con tropismo pulmonar mejorado y usos de las mismas

Country Status (10)

Country Link
US (1) US20260014275A1 (cg-RX-API-DMAC7.html)
EP (1) EP4490301A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025508059A (cg-RX-API-DMAC7.html)
KR (1) KR20240154633A (cg-RX-API-DMAC7.html)
CN (1) CN119213135A (cg-RX-API-DMAC7.html)
AU (1) AU2023230885A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254571A1 (cg-RX-API-DMAC7.html)
IL (1) IL315490A (cg-RX-API-DMAC7.html)
MX (1) MX2024010938A (cg-RX-API-DMAC7.html)
WO (1) WO2023172873A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102933125B1 (ko) 2024-02-01 2026-03-04 주식회사 글루진테라퓨틱스 평활근 세포 특이적 유전자 전달이 가능한 아데노연관바이러스 벡터
WO2026072591A1 (en) * 2024-09-25 2026-04-02 4D Molecular Therapeutics Inc. Combination therapy with adeno-associated virus and cftr modulator(s) for treatmet of cftr

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3684423T5 (da) * 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
US11707487B2 (en) * 2020-04-13 2023-07-25 Affyimmune Therapeutics, Inc. EpCAM antibody and CAR-T cells
CN115552021A (zh) * 2020-04-27 2022-12-30 4D分子治疗有限公司 用于肺递送的腺相关变体、制剂和方法

Also Published As

Publication number Publication date
CA3254571A1 (en) 2023-09-14
WO2023172873A3 (en) 2023-10-19
US20260014275A1 (en) 2026-01-15
KR20240154633A (ko) 2024-10-25
WO2023172873A2 (en) 2023-09-14
IL315490A (en) 2024-11-01
JP2025508059A (ja) 2025-03-21
CN119213135A (zh) 2024-12-27
AU2023230885A1 (en) 2024-09-26
EP4490301A2 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
ZA202210026B (en) Adeno-associated variants, formulations and methods for pulmonary delivery
JP7607007B2 (ja) 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
US7427396B2 (en) AAV vectors for gene delivery to the lung
JP2020010684A5 (cg-RX-API-DMAC7.html)
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
PH12020550706A1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
MX2022015048A (es) Viriones de virus adenoasociados con variantes de capsides y metodos de uso de estos.
MX2019010910A (es) Viriones de virus adenoasociados con capsides variantes y metodos para su uso.
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
NZ748395A (en) Adeno-associated virus variant capsids and methods of use thereof
JP2017518271A5 (cg-RX-API-DMAC7.html)
WO2023172873A3 (en) Adeno-associated virus variant capsids with improved lung tropism and uses thereof
WO2022229702A3 (en) Aav8 capsid variants with enhanced liver targeting
KR20220158674A (ko) Aav5의 단리 및 변형된 vp1 캡시드 단백질
WO2022229703A3 (en) New aav8 based immune escaping variants
PH12022551878A1 (en) Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
EP4159863A1 (en) Codon-optimized nucleic acid encoding smn1 protein
Sen et al. Cellular unfolded protein response against viruses used in gene therapy
MX2022012279A (es) Variantes de capsides de aav y usos de los mismos.
Liu et al. Advances in viral-vector systemic cytokine gene therapy against cancer
US12319714B2 (en) Compositions and methods for treating viral infections
WO2024220461A3 (en) Aav capsid proteins having mutations in the vp1 region
WO2024060463A1 (zh) 改进的人凝血因子viii基因表达盒及其应用
CN113454226B (zh) 用于治疗糖原贮积病的方法和组合物
US20220282279A1 (en) Compositions and methods for treating and preventing coronavirus infections